PET Imaging in Animal Models of Alzheimer's Disease

• Published in: Frontiers in neuroscience Vol. 16; p. 872509
• Main Authors: Chen, Baosheng, Marquez-Nostra, Bernadette, Belitzky, Erika, Toyonaga, Takuya, Tong, Jie, Huang, Yiyun, Cai, Zhengxin
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 24.05.2022
• Subjects: Alzheimer’s disease; neurodegeneration; Neuroscience; positron emission tomography; SV2A; tau; β-amyloid (Aβ); Alzheimer’s disease; neuroinflamamation; SV2A; neurodegeneration; tau; animal model; positron emission tomography; β-amyloid (Aβ)
• ISSN: 1662-4548; 1662-453X; 1662-453X
• DOI: 10.3389/fnins.2022.872509

The successful development and translation of PET imaging agents targeting β-amyloid plaques and hyperphosphorylated tau tangles have allowed for detection of these hallmarks of Alzheimer's disease (AD) antemortem. Amyloid and tau PET have been incorporated into the A/T/N scheme for AD characterization and have become an integral part of ongoing clinical trials to screen patients for enrollment, prove drug action mechanisms, and monitor therapeutic effects. Meanwhile, preclinical PET imaging in animal models of AD can provide supportive information for mechanistic studies. With the recent advancement of gene editing technologies and AD animal model development, preclinical PET imaging in AD models will further facilitate our understanding of AD pathogenesis/progression and the development of novel treatments. In this study, we review the current state-of-the-art in preclinical PET imaging using animal models of AD and suggest future research directions.